Amid investor pressure to split up its CEO and chairman roles, embattled Allergan is giving in—but only a bit.
Allergan will support an investor resolution to split up the jobs, the company said on Tuesday, shortly after hedge fund manager David Tepper renewed his demand that it do so. The catch? The split wouldn’t happen until Allergan’s next CEO rotation—meaning current CEO and Chairman Brent Saunders would keep wearing both hats.
That wasn’t enough for Tepper, who once again blasted Allergan’s board after Tuesday’s announcement. The latest move “falls short of improved governance and once again lays bare your reluctance to hold management accountable for its dismal performance,” Tepper wrote.
Saunders and his current board are responsible for more than $13 billion in balance sheet write-downs in 15 of the last 16 quarters, Tepper argued, plus “embarrassing legal initiatives,” a “failed acquisition strategy resulting in an underperforming product pipeline,” a lower stock price and “stunningly excessive” management compensation.
“That the board believes a toothless resolution will even begin to address these issues speaks to your subservience to the management team you have compensated so lavishly,” the investor wrote.
Tepper has repeatedly advocated for change at Allergan. In a letter early this month, the hedge fund manager wrote that a “growing majority” of S&P 500 companies split their CEO and chairman jobs, and 40% of Allergan shareholders recently voted to split up the roles “despite little fanfare or support from an organized campaign.”
Still, the company resisted, which Tepper said was worrisome, considering Allergan’s struggles in recent years. The company’s shares are down about 50% from a peak in the summer of 2015.
Among Allergan’s recent problems, the company this month rolled out 2019 sales guidance lower than analysts had projected, and disclosed it’s canceling a previously planned sale of its women’s health unit. Further, the drugmaker in 2017 made itself the center of controversy with a patent licensing tactic that involved a Native American tribe, and it now faces competitive threats to top sellers Restasis and Botox.
Allergan’s latest announcement came along with news that former Celgene CEO Bob Hugin is joining the company’s board after a failed run for a U.S. Senate seat. Hugin, an influential pharma executive, is the sixth new director at Allergan since 2017.
Hugin spent nearly two decades at Celgene and served as its CEO from 2010 to 2016. More recently, he relinquished his chairman role and sought a U.S. Senate seat representing New Jersey; he lost in the race to Democratic incumbent Bob Menendez.
Meanwhile, Hugin’s former company is making headlines with its decision to accept a $74 billion buyout bid from Bristol-Myers Squibb. The combined company would be a leader in oncology, cardiovascular diseases and inflammatory diseases, executives have said. Announced early this year, the Bristol-Myers/Celgene deal would be one of the biggest pharma mergers of all time.
By Eric Sagonowsky
Source: Fierce Pharma
The deal will enhance Merck’s expertise in developing and manufacturing mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and various other diseases.
It’s the first significant visual redesign for Pfizer in 70 years since the company began using the blue oval background. The tagline outlining Pfizer’s purpose, “Breakthroughs that change patients’ lives,” remains the same.
The massive growth of gene therapy research and development over the last few years has boosted demand for viral vectors, the engineered viruses used to deliver therapeutic genes into patients’ bodies. Tokyo-based Fujifilm Diosynth Biotechnologies is stepping up to meet that demand.